Teva UK Limited Welcomes DH Consultation on COPD Strategy

CASTLEFORD, England, April 19, 2010 - Teva UK Limited has welcomed the Department of Health's (DH) consultation
on a Strategy for Services for Chronic Obstructive Pulmonary Disease (COPD).

As well as outlining a strategy for COPD services, the document also
incorporates a strategy for asthma management.

Says Robyn Hughes, Director for Primary & Secondary Care at Teva: "Teva
wholeheartedly supports the DH proposed strategy for COPD. The strategy seeks
to put patient health at the centre by enabling patients to manage their
condition themselves, and we believe this is key to its successful
implementation."

Adds Robyn: "We know it's important that patients understand the
importance of lung health and risk factors, and these proposals seek to
address the current situation where we have an estimated 2 million
undiagnosed UK patients with COPD."1

The report also highlights issues around patients with asthma, and the
importance of patient inhaler technique and of taking preventer medicine on a
daily basis.1

The aim of the DH strategy is to ensure that COPD and asthma services are
effective, give the patient control of their condition, and provide good
value for money for taxpayers. The consultation runs until the end of April
2010.

Teva's sales of respiratory products such as inhalers make it the second
largest pharmaceutical company in the UK market by number of respiratory
products sold.

To find out more about Teva, visit www.tevauk.com.

Reference:

1. www.dh.gov.uk/en/Consultations/Liveconsultations/DH_112977
1/4/2010

Notes to editors:

Teva UK Limited is one of the UK's leading pharmaceutical manufacturers,
with a presence in the generics, branded respiratory and hospitals markets.
Measured by the volume of boxes supplied, it is the biggest single medicines
supplier to the NHS. With over 500 product lines, it has the widest range of
any UK generic pharmaceutical company and has a number of respiratory
products including the Qvar(R) (beclometasone dipropionate) CFC-free inhaler.

For media enquiries, telephone the Teva Communications team on
+44(0)1977-628500, or email media.enquiries@tevauk.com.

For media enquiries, telephone the Teva Communications team on +44(0)1977-628500, or email media.enquiries at tevauk.com.